<p>FutureTech II Acquisition Corp.是一家空白支票公司，旨在与一家或多家企业进行合并、资本股票交换、资产收购、股票购买、重组或类似的商业组合，已发布其 2025 年第二季度的 10-Q 报告。该报告详细概述了公司在此期间的财务表现和主要业务活动。</p>
<p><strong>财务亮点</strong></p>
<p><strong>净收入：</strong></p>
<ul>
<li>截至 2025 年 6 月 30 日的三个月内，公司报告净亏损为 80,647 美元，其中包括投资收入 72,477 美元，部分抵消了 138,735 美元的费用和 14,389 美元的税费。</li>
<li>截至 2025 年 6 月 30 日的六个月内，公司报告净亏损为 370,320 美元，其中包括投资收入 272,304 美元，部分抵消了 592,572 美元的费用和 50,052 美元的税费。</li>
</ul>
<p><strong>每股净收入：</strong></p>
<ul>
<li>截至 2025 年 6 月 30 日的三个月内，普通股的基本和稀释每股净收入（亏损）为可赎回股份$(0.19) 和不可赎回股份$(0.04)。</li>
<li>截至 2025 年 6 月 30 日的六个月内，普通股的基本和稀释每股净收入（亏损）为可赎回股份$(0.04) 和不可赎回股份$(0.15)。</li>
</ul>
<p><strong>流动性和资本资源：</strong></p>
<ul>
<li>截至 2025 年 6 月 30 日，公司现金为 160,723 美元，没有现金等价物，六个月内用于经营活动的现金为 1,187,204 美元。</li>
</ul>
<p><strong>投资活动提供的现金：</strong></p>
<ul>
<li>截至 2025 年 6 月 30 日的六个月内，投资活动提供的现金为 17,585,764 美元，主要由于从信托账户提取的现金为 17,822,230 美元，部分抵消了存入信托账户的 236,466 美元现金。</li>
</ul>
<p><strong>融资活动使用的现金：</strong></p>
<ul>
<li>截至 2025 年 6 月 30 日的六个月内，融资活动使用的现金为 16,294,605 美元，主要由于赎回支付的现金为 17,400,674 美元，部分抵消了来自转移代理的 695,024 美元收入和来自相关方债务发行的 411,045 美元收入。</li>
</ul>
<p><strong>业务亮点</strong></p>
<p><strong>业务概述：</strong> FutureTech II Acquisition Corp 是一家空白支票公司，旨在与一家或多家企业进行合并、资本股票交换、资产收购、股票购买、重组或类似的商业组合。该公司是一家新兴成长公司，面临相关风险。</p>
<p><strong>组合期延长：</strong> 公司多次延长其商业组合期，最新的延长允许其在 2025 年 8 月 18 日之前完成初始商业组合。此延长通过每月存入信托账户实现。</p>
<p><strong>与 Longevity Biomedical Inc.的合并协议：</strong> FutureTech II 已与 Longevity Biomedical Inc.签署合并协议，涉及 Longevity 与 FutureTech II 的子公司合并，成为全资子公司。公司的普通股预计在合并后以 “LBIO” 的股票代码在纳斯达克上市。</p>
<p><strong>PIPE 认购协议：</strong> 公司与一位投资者签署了认购协议，购买 1,000,000 股 A 类普通股，价格为每股 5.00 美元，前提是与 Longevity 的商业组合完成。</p>
<p><strong>赞助商营运资金贷款：</strong> 为了融资与 Longevity 商业组合相关的交易成本和持续运营，公司向赞助商发行了一份最高为 1,500,000 美元的本票。</p>
<p><strong>遵守纳斯达克上市标准：</strong> 公司在满足纳斯达克上市标准方面面临挑战，导致从纳斯达克全球市场转移到纳斯达克资本市场。由于未在规定时间内完成商业组合，公司目前在场外交易。</p>
<p><strong>零利息可转换票据：</strong> 公司向几位投资者发行了总额为 1,025,000 美元的零利息可转换票据，投资者可选择在商业组合后将本金转换为公司的股份。</p>
<p><strong>未来展望：</strong> 公司专注于完成与 Longevity Biomedical Inc.的商业组合，并已延长其商业组合期，以确保有足够的时间进行交易。公司还在努力恢复对上市标准的合规性，并预计其证券将在场外市场报价。</p>
<p>SEC 备案：FutureTech II Acquisition Corp. [ FTII ] - 10-Q -2025 年 8 月 22 日</p>

FTIIU

FTII

<p>FutureTech II Acquisition Corp. 发布了其 2025 年第二季度的 SEC 10-Q 报告，报告显示该季度净亏损为 80,647 美元，六个月的净亏损为 370,320 美元。该公司已将其业务合并期限延长至 2025 年 8 月 18 日，并与 Longevity Biomedical Inc.签署了合并协议。FutureTech II 还面临着纳斯达克上市标准的合规挑战，并已发行总额为 1,025,000 美元的零息可转换票据。该公司旨在完成合并并重新获得上市标准的合规性</p>

<p>FutureTech II Acquisition Corp., a blank check company formed to effectuate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, has released its Form 10-Q report for the second quarter of 2025. The report provides a detailed overview of the company's financial performance and key business activities during the period.</p>
<div class="lb-trans"><p>FutureTech II Acquisition Corp.是一家空白支票公司，旨在与一家或多家企业进行合并、资本股票交换、资产收购、股票购买、重组或类似的商业组合，已发布其 2025 年第二季度的 10-Q 报告。该报告详细概述了公司在此期间的财务表现和主要业务活动。</p>
</div><p><strong>Financial Highlights</strong></p>
<div class="lb-trans"><p><strong>财务亮点</strong></p>
</div><p><strong>Net Income:</strong></p>
<div class="lb-trans"><p><strong>净收入：</strong></p>
</div><ul>
<li>For the three months ended June 30, 2025, the company reported net losses of $80,647, which consisted of investment income of $72,477, partially offset by expenses of $138,735 and tax expense of $14,389.</li>
<li>For the six months ended June 30, 2025, the company reported net losses of $370,320, which consisted of investment income of $272,304, partially offset by expenses of $592,572 and tax expense of $50,052.</li>
</ul>
<div class="lb-trans"><ul>
<li>截至 2025 年 6 月 30 日的三个月内，公司报告净亏损为 80,647 美元，其中包括投资收入 72,477 美元，部分抵消了 138,735 美元的费用和 14,389 美元的税费。</li>
<li>截至 2025 年 6 月 30 日的六个月内，公司报告净亏损为 370,320 美元，其中包括投资收入 272,304 美元，部分抵消了 592,572 美元的费用和 50,052 美元的税费。</li>
</ul>
</div><p><strong>Net Income Per Share:</strong></p>
<div class="lb-trans"><p><strong>每股净收入：</strong></p>
</div><ul>
<li>For the three months ended June 30, 2025, basic and diluted net income (loss) per share of common stock was $(0.19) for redeemable shares and $(0.04) for non-redeemable shares.</li>
<li>For the six months ended June 30, 2025, basic and diluted net income (loss) per share of common stock was $(0.04) for redeemable shares and $(0.15) for non-redeemable shares.</li>
</ul>
<div class="lb-trans"><ul>
<li>截至 2025 年 6 月 30 日的三个月内，普通股的基本和稀释每股净收入（亏损）为可赎回股份$(0.19) 和不可赎回股份$(0.04)。</li>
<li>截至 2025 年 6 月 30 日的六个月内，普通股的基本和稀释每股净收入（亏损）为可赎回股份$(0.04) 和不可赎回股份$(0.15)。</li>
</ul>
</div><p><strong>Liquidity and Capital Resources:</strong></p>
<div class="lb-trans"><p><strong>流动性和资本资源：</strong></p>
</div><ul>
<li>As of June 30, 2025, the company had $160,723 in cash and no cash equivalents, with cash used in operating activities amounting to $1,187,204 for the six months ended June 30, 2025.</li>
</ul>
<div class="lb-trans"><ul>
<li>截至 2025 年 6 月 30 日，公司现金为 160,723 美元，没有现金等价物，六个月内用于经营活动的现金为 1,187,204 美元。</li>
</ul>
</div><p><strong>Cash Provided by Investing Activities:</strong></p>
<div class="lb-trans"><p><strong>投资活动提供的现金：</strong></p>
</div><ul>
<li>For the six months ended June 30, 2025, cash provided by investing activities was $17,585,764 due to cash withdrawn from the Trust Account of $17,822,230, partially offset by cash deposited into the Trust Account of $236,466.</li>
</ul>
<div class="lb-trans"><ul>
<li>截至 2025 年 6 月 30 日的六个月内，投资活动提供的现金为 17,585,764 美元，主要由于从信托账户提取的现金为 17,822,230 美元，部分抵消了存入信托账户的 236,466 美元现金。</li>
</ul>
</div><p><strong>Cash Used in Financing Activities:</strong></p>
<div class="lb-trans"><p><strong>融资活动使用的现金：</strong></p>
</div><ul>
<li>For the six months ended June 30, 2025, cash used in financing activities was $16,294,605 due to $17,400,674 in cash paid for redemptions, partially offset by proceeds from Transfer Agent of $695,024 and proceeds from issuance of debt – related party of $411,045.</li>
</ul>
<div class="lb-trans"><ul>
<li>截至 2025 年 6 月 30 日的六个月内，融资活动使用的现金为 16,294,605 美元，主要由于赎回支付的现金为 17,400,674 美元，部分抵消了来自转移代理的 695,024 美元收入和来自相关方债务发行的 411,045 美元收入。</li>
</ul>
</div><p><strong>Business Highlights</strong></p>
<div class="lb-trans"><p><strong>业务亮点</strong></p>
</div><p><strong>Business Overview:</strong> FutureTech II Acquisition Corp is a blank check company formed to effectuate a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company is an emerging growth company and is subject to the associated risks.</p>
<div class="lb-trans"><p><strong>业务概述：</strong> FutureTech II Acquisition Corp 是一家空白支票公司，旨在与一家或多家企业进行合并、资本股票交换、资产收购、股票购买、重组或类似的商业组合。该公司是一家新兴成长公司，面临相关风险。</p>
</div><p><strong>Extension of Combination Period:</strong> The company has extended its business combination period multiple times, with the latest extension allowing it to consummate its initial business combination by August 18, 2025. This extension is facilitated by monthly deposits into the trust account.</p>
<div class="lb-trans"><p><strong>组合期延长：</strong> 公司多次延长其商业组合期，最新的延长允许其在 2025 年 8 月 18 日之前完成初始商业组合。此延长通过每月存入信托账户实现。</p>
</div><p><strong>Merger Agreement with Longevity Biomedical Inc.:</strong> FutureTech II has entered into a merger agreement with Longevity Biomedical Inc., which involves Longevity merging with a subsidiary of FutureTech II, becoming a wholly-owned subsidiary. The company's common stock is expected to list on NASDAQ under the ticker symbol 'LBIO' post-merger.</p>
<div class="lb-trans"><p><strong>与 Longevity Biomedical Inc.的合并协议：</strong> FutureTech II 已与 Longevity Biomedical Inc.签署合并协议，涉及 Longevity 与 FutureTech II 的子公司合并，成为全资子公司。公司的普通股预计在合并后以 “LBIO” 的股票代码在纳斯达克上市。</p>
</div><p><strong>PIPE Subscription Agreement:</strong> The company entered into a subscription agreement with an investor for the purchase of 1,000,000 shares of Class A Common Stock at $5.00 per share, contingent upon the consummation of the business combination with Longevity.</p>
<div class="lb-trans"><p><strong>PIPE 认购协议：</strong> 公司与一位投资者签署了认购协议，购买 1,000,000 股 A 类普通股，价格为每股 5.00 美元，前提是与 Longevity 的商业组合完成。</p>
</div><p><strong>Sponsor Working Capital Loans:</strong> To finance transaction costs related to the Longevity Business Combination and ongoing operations, the company issued a promissory note to the sponsor for up to $1,500,000.</p>
<div class="lb-trans"><p><strong>赞助商营运资金贷款：</strong> 为了融资与 Longevity 商业组合相关的交易成本和持续运营，公司向赞助商发行了一份最高为 1,500,000 美元的本票。</p>
</div><p><strong>Compliance with Nasdaq Listing Standards:</strong> The company faced challenges in meeting Nasdaq's listing standards, resulting in a transfer from the Nasdaq Global Market to the Nasdaq Capital Market. The company is now trading over the counter following a delisting notice due to not completing a business combination within the required timeframe.</p>
<div class="lb-trans"><p><strong>遵守纳斯达克上市标准：</strong> 公司在满足纳斯达克上市标准方面面临挑战，导致从纳斯达克全球市场转移到纳斯达克资本市场。由于未在规定时间内完成商业组合，公司目前在场外交易。</p>
</div><p><strong>Zero Interest Convertible Notes:</strong> The company issued zero interest convertible notes totaling $1,025,000 to several investors, with the option to convert the principal amount into shares of the company post-business combination.</p>
<div class="lb-trans"><p><strong>零利息可转换票据：</strong> 公司向几位投资者发行了总额为 1,025,000 美元的零利息可转换票据，投资者可选择在商业组合后将本金转换为公司的股份。</p>
</div><p><strong>Future Outlook:</strong> The company is focused on completing its business combination with Longevity Biomedical Inc. and has extended its business combination period to ensure sufficient time for the transaction. The company is also working on regaining compliance with listing standards and expects its securities to be quoted on the over-the-counter market.</p>
<div class="lb-trans"><p><strong>未来展望：</strong> 公司专注于完成与 Longevity Biomedical Inc.的商业组合，并已延长其商业组合期，以确保有足够的时间进行交易。公司还在努力恢复对上市标准的合规性，并预计其证券将在场外市场报价。</p>
</div><p>SEC Filing: FutureTech II Acquisition Corp. [ FTII ] - 10-Q - Aug. 22, 2025</p>
<div class="lb-trans"><p>SEC 备案：FutureTech II Acquisition Corp. [ FTII ] - 10-Q -2025 年 8 月 22 日</p>
</div>

FutureTech II Acquisition Corp. SEC 10-Q 季度报告